证券代码：688117 证券简称：圣诺生物 公告编号：2026-003 成都圣诺生物科技股份有限公司 2025年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以成都圣诺生物 科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币元 ■ 3、影响经营业绩的主要因素 报告期内，公司持续专注于主营业务多肽药物CDMO、原料药和制剂的协同发展，得益于全球多肽药物 市场降糖、减重领域的药品需求持续放量，使得公司GLP-1原料药销量大增，经营业绩大幅提升。 （二）上表中有关项目增减变动幅度达30%以上的主要原因 注：1.本报告期初数同法定披露的上年年末数。 2.表中财务数据及指标均以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准；表 中增减变动幅度数据如有尾差，系四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状 ...

Core Viewpoint - The company is planning to transfer 100% equity of its wholly-owned subsidiary, Hunan Sailong Biological Pharmaceutical Co., Ltd., through a public listing to optimize resource allocation and improve operational efficiency [2][5]. Group 1: Equity Transfer Details - The initial public listing for the transfer of Sailong Bio's 100% equity was held from January 23 to February 12, 2026, with a starting price set at RMB 86.95 million based on an assessment by Beijing Kunyuan Zhicheng Asset Appraisal Co., Ltd. [2] - Due to a lack of qualified buyers during the initial listing period, the company decided to reduce the listing price by 10% to RMB 78.255 million for the next round of public listing [2][3]. - If no qualified buyers are found after the next listing period, the company will apply for subsequent rounds of listing, with each round's price reduced by 10% from the previous [3]. Group 2: Financial Performance of Sailong Bio - Sailong Bio has been operating at a loss, reporting a loss of RMB 2.5186 million for the fiscal year 2024, which expanded to RMB 15.0288 million in the first three quarters of 2025 [4]. - Revenue for the first three quarters of 2025 was RMB 8.9229 million, while the total revenue for 2024 was RMB 10.9844 million [4]. - As of September 30, 2025, Sailong Bio's net assets were RMB 25.0493 million, down from RMB 40.077 million at the end of 2024 [4]. Group 3: Strategic Implications - The ongoing public listing of Sailong Bio's equity is aimed at optimizing the company's resource allocation, revitalizing assets, and enhancing operational efficiency, which aligns with the company's strategic development plan [5]. - The company emphasizes that the transaction will not harm the interests of shareholders, particularly minority shareholders, and the proceeds will be used for business development [5]. - The company retains the right to terminate the listing if no qualified buyers are found, and the final transaction price and counterparties will depend on the results of the public listing [3][5].

Core Viewpoint - The company Guangkang Biochemical announced a share reduction plan by specific shareholders, which may indicate a potential shift in investor sentiment and could impact the stock price in the near term [1][10]. Shareholder Reduction Plans - Specific shareholders, including Huatuo Zhiying No. 2, Huatuo Zhiyuan No. 3, and Ruihong Kaiyin No. 1, plan to reduce their holdings within three months from the announcement date through centralized bidding and block trading [1][4]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 plan to collectively reduce up to 1.3198 million shares, accounting for 1.7835% of the total share capital, while Ruihong Kaiyin No. 1 plans to reduce up to 1.98 million shares, representing 2.6757% of the total share capital [4][6]. Historical Context of Share Reductions - The shareholders are preparing for a "clearance-style" reduction, with Ruihong Kaiyin No. 1 having previously announced a similar reduction plan in October 2025, which was not executed [7]. - Huatuo Zhiying No. 2 and Huatuo Zhiyuan No. 3 had also announced a reduction plan in September 2025, resulting in a decrease in Huatuo Zhiyuan No. 3's holding from 0.6022% to 0.5884% [7]. Company Background - Guangkang Biochemical is a national high-tech enterprise specializing in the research, production, and sales of pesticide active ingredients, intermediates, and formulations [8]. - The company received a warning letter from the Guangdong Securities Regulatory Bureau a month prior to the announcement of the share reduction [10]. Financial Management Issues - From July 2023 to August 2025, the company used raised funds for cash management, purchasing 179 financial products, of which 158 were non-principal guaranteed products. The company did not adequately disclose the risks associated with these investments in its reports [10]. Stock Performance - The timing of the reduction announcement coincides with a nearly 20% rebound in the company's stock price from February 6 to February 11. Following the announcement, the stock initially dipped but later rebounded, closing up over 5% [10].

Group 1: R&D and Client Collaboration - The company focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to provide raw materials for 8 original drug varieties and plans to add 1-2 new commercialized raw materials annually [2] - Established long-term strategic partnerships with renowned pharmaceutical companies such as Novartis and Sanofi, expanding collaboration from sartan raw materials to non-sartan raw materials, patent-expired drugs, and innovative drug projects [2] Group 2: CDMO Business Strategy - The company has built a solid service foundation and professional competitiveness in the generic drug raw material field, leveraging a comprehensive GMP system and compliance capabilities [3] - The CDMO business focuses on strategic clients, prioritizing high-potential projects during patent periods and late-stage development, ensuring significant scale benefits and customer loyalty [3] Group 3: Business Growth Outlook for 2026 - Raw material segment: Sartan raw materials' revenue share is expected to decline, while non-sartan raw materials (e.g., sitagliptin, ezetimibe) are projected to be core growth drivers, maintaining rapid growth and potential margin improvement [4] - CDMO business: Revenue may face pressure due to changing client demands, but the company is actively pursuing new project opportunities to maintain stability [4] - Formulation business: Expected to continue rapid growth due to expanding market channels, despite a small revenue base [4] - Acetonitrile project: The annual production capacity of 20,000 tons has passed acceptance in January 2026, targeting high-end fields such as peptides and small nucleic acids [4] Group 4: Profitability and Cost Management - Sartan raw materials maintain a gross margin above 30% despite competitive pricing pressures, with expectations for stable margins as prices stabilize [5] - Non-sartan raw materials' gross margin is expected to improve as production increases and costs decrease, aiming to align closer to sartan products [5] Group 5: R&D and Sales Expenses - The company's overall R&D investment will remain stable at approximately 2.5-2.8 billion annually, with a rising proportion allocated to raw materials and CDMO R&D [5] - Sales expenses are increasing rapidly in the formulation business due to its growth, with the company enhancing marketing control through digital systems [5]

Group 1 - The article highlights the transformation of the Sanfang Industrial Park in Haimen District, Nantong City, from a historical industrial hub to a modern industrial highland, driven by innovation and industry [1] - Zhongxing Energy, a leading company in the steel pipe industry, has significantly improved its production efficiency with a fully automated acid washing line, increasing its annual capacity to 70,000 tons while reducing labor needs to just 8 workers [1] - The intelligent logistics warehouse of Weibosite has enhanced order response times for major brands like Uniqlo and ZARA through a digital twin technology-integrated storage system, promoting standardization and high-end development in the fabric industry [1] Group 2 - In the life and health sector, Jiangsu Huiju Pharmaceutical, recognized as a "little giant" enterprise, leads the industry with an integrated strategy of raw materials and formulations, serving over 300 global clients [2] - The new materials industry is experiencing robust growth, with companies like Ronghui Lithium and Xinwei Nickel Cobalt driving the development of lithium battery materials and optical communication technologies, creating a comprehensive industrial ecosystem [2] - The Sanfang Industrial Park reported an industrial output value of 3.812 billion yuan in the first half of 2025, reflecting a year-on-year growth of 13.37%, alongside a 42% increase in general public budget revenue [2] Group 3 - The park is leveraging national strategies such as the Yangtze River Economic Belt to cultivate a cluster of technology-driven enterprises, positioning itself as a benchmark for industrial transformation and innovation in the region [3] - The park's leadership emphasizes the importance of a supportive business environment, aiming to attract high-end resources and facilitate the transformation of research achievements into practical applications [3] - The revitalization of the Qinglong Port area combines historical industrial heritage with modern innovation, enhancing tourism value and benefiting from improved transportation links to Shanghai [3]

Core Viewpoint - Tianyu Co., Ltd. expects a significant year-on-year increase in net profit attributable to shareholders in 2025, indicating a stable growth trend in overall performance [2] Financial Performance - The company reported that the financial indicators for the fourth quarter, including sales net profit, were affected by changes in product sales structure, cost expenses, and asset impairment provisions [2] - The company will provide specific details in the upcoming 2025 Annual Report [2] Business Operations - Current production and operations of the company are normal, with steady growth in core business segments, including raw materials and formulation business [2]

Core Viewpoint - The report highlights that China's biopharmaceutical industry is transitioning from a "cost advantage" to "innovation-driven" growth, with overseas expansion becoming a second growth curve for innovative drug companies, indicating a shift from "heavy R&D" to "strong commercialization" [1][3]. Group 1: Industry Growth and Financial Performance - By the first three quarters of 2025, China's innovative drug sector revenue reached 48.83 billion yuan, reflecting a year-on-year growth of 22.1% [3]. - The total amount of foreign licensing for Chinese innovative drugs exceeded 100 billion USD in the first ten months of 2025, averaging nearly 300 million USD per day in international capital for Chinese original innovative drugs [3]. - Several companies have turned losses into profits, marking a period where the profitability of the Chinese biopharmaceutical industry is entering a realization phase [3]. Group 2: Evolution of Export Structure - The report outlines a significant transformation in China's biopharmaceutical exports, moving from low-value raw materials to high-value formulations, innovative drugs, and high-end medical devices [6][13]. - The overseas market strategy has diversified, focusing on consolidating developed markets while exploring emerging markets, with the U.S. remaining a primary target for innovative drugs [6][8]. Group 3: Outbound Strategies and Models - Chinese biopharmaceutical companies have developed a diverse set of outbound strategies, including independent expansion, co-development, licensing-out, NewCo models, and distribution agency, evolving from simple equity transactions to deeper participation in the global value chain [9][11]. - The limitations of traditional licensing-out models are becoming apparent, while Co-Co and NewCo models facilitate deeper involvement in global R&D, registration, and commercialization processes [9][11]. Group 4: Future Trends and Strategic Recommendations - The report identifies four key trends for 2026 and beyond: continuous evolution of technological frontiers, a shift from equity transactions to strategic symbiosis, the growing importance of emerging markets, and enhanced collaborative effects across the industry chain [14]. - Companies are encouraged to build long-term capabilities in compliance, commercialization, and brand image, moving from "industry outbound" to "global brand building" [17][18].

Core Viewpoint - Jincheng Pharmaceutical has announced an annual performance forecast indicating a significant decline in net profit for 2025, with expectations of a decrease of 73.07% to 79.67% year-on-year [1] Financial Performance Summary - The company anticipates a net profit attributable to shareholders of 40 million to 53 million yuan for 2025, which represents a substantial decrease compared to the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 28 million and 37 million yuan, reflecting a year-on-year decline of 79.43% to 84.44% [1] Reasons for Performance Change - The primary reasons for the decline in performance include: 1. A slowdown in product market demand, intense industry competition, and the impact of national centralized procurement policies, leading to a decrease in both prices and sales volume for certain products in the intermediate and formulation segments [1] 2. An increase in asset impairment provisions for 2025 compared to the previous year, in response to industry and market changes [1] 3. The need for the company's subsidiaries, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Guangdong Landu Pharmaceutical Co., Ltd., to pay back taxes from previous years [1] - The impact of non-recurring gains and losses on net profit is estimated to be between 12 million and 16 million yuan [1]

Group 1 - On January 29, Haoyuan Pharmaceutical's stock fell by 5.68%, with a trading volume of 588 million yuan [1] - The financing data shows that on the same day, Haoyuan Pharmaceutical had a financing purchase amount of 64.30 million yuan and a net financing purchase of 8.90 million yuan [1] - As of January 29, the total balance of margin trading for Haoyuan Pharmaceutical was 631 million yuan, which accounts for 4.02% of its circulating market value [1] Group 2 - Haoyuan Pharmaceutical, established on September 30, 2006, is located in Shanghai and specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field [2] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42% [2] - For the period from January to September 2025, Haoyuan Pharmaceutical achieved an operating income of 2.06 billion yuan, representing a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million yuan, up by 65.09% [2] Group 3 - Since its A-share listing, Haoyuan Pharmaceutical has distributed a total of 160 million yuan in dividends, with 120 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders of Haoyuan Pharmaceutical include Hong Kong Central Clearing Limited as the second-largest shareholder, increasing its holdings by 2.35 million shares [3] - New institutional shareholders include China Europe Medical Innovation Stock A, holding 2.21 million shares, and Huatai-PineBridge Healthcare Mixed Fund, holding 1.41 million shares [3]

Core Viewpoint - Wihua New Materials (巍华新材) is engaged in the agricultural chemical industry, providing essential intermediates for pesticide production, indicating a strong integration of R&D, production, and sales capabilities [1] Company Overview - Wihua New Materials is involved in the production of agricultural raw materials, formulations, and intermediates, with a focus on herbicides and fungicides [1] - The company collaborates with Jiangsu Heyutai Chemical Co., Ltd., which was established in June 2013 with a registered capital of 120 million RMB, and is recognized as a national high-tech enterprise [1] Product and Market Position - Wihua New Materials supplies key intermediates necessary for the production of pesticides such as flumioxazin and pyraflufen-ethyl, highlighting its role in the agricultural chemical supply chain [1]